Lay Title: Engineered T Cells in MAGE A3/A6 expressing tumors
Technical Title: A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers
Disease Type: Metastatic Urothelial cancer and other solid tumors.
Basic information: The purpose of this study is to offer T cell therapy in patients with HLA-DPB1*04:01 Positive solid tumors expressing MAGE A3/A6.
Research Procedures (not a complete list): More details upon entering study will be provided in terms of biopsy requirements and treatment schedule. Patients will receive 3 days of chemotherapy as outpatient followed by hospitalization to receive the T cell therapy.
Eligibility Criteria (not a complete list)
For More Detailed Information, Contact:
ClinicalTrials.gov Identifier: NCT03139370